Old API Wind-down Ltd - Ordinary Shares ARLZQ

Brexit

[kuatolives]

At least we don't have any UK exposure right now, unlike Merus and Concordia. Uncertainty over the Brexit for the next couple of years will likely keep those names depressed for a while, as if Concordia didn't have enough problems as it is. ARLZ is still the best name in Canadian pharma going, with maybe GUD in the mix if they actually buy something before prices rebound. No more than 13 weeks now before Yosprala gets an answer from the FDA.  Could come any day now though.